Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.

Oncogene - 24 Apr 2014

Gang E J, Hsieh Y-T, Pham J, Zhao Y, Nguyen C, Huantes S, Park E, Naing K, Klemm L, Swaminathan S, Conway E M, Pelus L M, Crispino J, Mullighan C G, McMillan M, Müschen M, Kahn M, Kim Y-M

Abstract excerpt

Drug resistance in acute lymphoblastic leukemia (ALL) remains a major problem warranting new treatment strategies. Wnt/catenin signaling is critical for the self-renewal of normal hematopoietic progenitor cells. Deregulated Wnt signaling is evident in chronic and acute myeloid leukemia; however, little is known about ALL. Differential interaction of catenin with either the Kat3 coactivator CREBBP (CREB-binding...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asparaginase
Share to Bridged Bicyclo Compounds, Heterocyclic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dexamethasone

Share to Inhibitor of Apoptosis Proteins

Share to Pyrimidinones

Share to Sialoglycoproteins

Share to Survivin

Share to Vincristine

Source

Open in PubMed Open full text

Identifiers

PMID: 23728349
DOI: 10.1038/onc.2013.169
PMCID: PMC3994178

Genes

CREBBP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.PMID 23728349Read ↗

The Gamma Catenin/CBP Complex Maintains Survivin Transcription in β-catenin Deficient/Depleted Cancer CellsSemantic proximity Read ↗

PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation.Semantic proximity Read ↗

Wnt/β-catenin/CBP signaling maintains long-term murine embryonic stem cell pluripotencySemantic proximity Read ↗

Targeting CBP/p300 Overcomes Acquired Vincristine Resistance in MedulloblastomaSemantic proximity Read ↗

Inhibiting H3K27 Demethylases Downregulates CREB ‐ CREBBP , Overcoming Resistance in Relapsed Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.Semantic proximity Read ↗

Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer.Semantic proximity Read ↗

Concurrent inhibition of p300/CBP and FLT3 enhances cytotoxicity and overcomes resistance in acute myeloid leukemiaSemantic proximity Read ↗

Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic CancerSemantic proximity Read ↗

Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor ActivitySemantic proximity Read ↗

Noncanonical β-catenin interactions promote leukemia-initiating activity in early T-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

Relapse-associated AURKB blunts the glucocorticoid sensitivity of B cell acute lymphoblastic leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.